CTEP

EV Range's Charging Network now includes LG electric vehicle charger

Retrieved on: 
Monday, March 4, 2024
SAN, EV, Architecture, Multimedia, Columbia Mountains, CTEP, AC, Ecosystem, LG, Running, Software, LED, Fireworks

EV Range is the first electric vehicle charging software network authorized to distribute these new LG chargers.

Key Points: 
  • EV Range is the first electric vehicle charging software network authorized to distribute these new LG chargers.
  • All LG chargers sold by EV Range are preconfigured to be remotely managed via the EV Range charger station management software and accessible to consumers with the EV Range pay app.
  • "We are thrilled to introduce the LG charger to our network," said Carl Pancutt, CEO of EV Range.
  • "Combining EV Range's best in class cloud-based Charger Station Management Software, customizable EV Range pay app, and 24-7 support services with LG's new EV charging station is a combination that exemplifies the best in electric vehicle charging innovation.

ABB E-mobility delivers Build America- Buy America and NACS-ready EV chargers to first NEVI site in Southeastern US

Retrieved on: 
Tuesday, February 20, 2024
ISO, Buy America Act, EV, Federal Highway, Federal Highway Administration, Commonwealth, Record, Transport, Interstate Highway System, Southeastern United States, CTEP, ABB, Terra, Business development, NTEP, OCPP, NACS, BABA, Certification, Policy, Circle K, Electric battery

The site will be built with ABB E-mobility Terra 184 chargers, which are Build America, Buy America (BABA) compliant, meet the NEVI technical minimum standards, and are "NACS-ready".

Key Points: 
  • The site will be built with ABB E-mobility Terra 184 chargers, which are Build America, Buy America (BABA) compliant, meet the NEVI technical minimum standards, and are "NACS-ready".
  • ABB E-mobility shares this commitment, providing NEVI compliant T184 fast chargers to partners awarded NEVI funding in over a half dozen states across the United States.
  • ABB E-mobility has been designing and manufacturing EV chargers for nearly 15 years and electrification equipment for over a century.
  • Terra 184 chargers manufactured at our South Carolina-based operations meet the "Phase II" requirements for Build America, Buy America Act of 55% US cost of components which is applicable to multiple Federal Programs, including NEVI.

First Phosphate Receives Letter of Interest in the Amount of up to US$170 Million from the Export-Import Bank of the United States (EXIM)

Retrieved on: 
Friday, September 29, 2023
Export–Import Bank of the United States, OTC Markets Group, Phosphate, Exim Bank, CSE, Policy, Saguenay, EXIM, FSE, LFP, USD, LOI, Republic, Corporation, CTEP, Letter, PPA, Rare-earth element

Moreover, the transaction may be eligible for special consideration under Section 402 of EXIM's 2019 reauthorization (P.L.

Key Points: 
  • Moreover, the transaction may be eligible for special consideration under Section 402 of EXIM's 2019 reauthorization (P.L.
  • "We thank EXIM bank and US policy makers for working to build a strong North American LFP battery supply chain.
  • First Phosphate notes that the LOI does not represent a financing commitment and does not guarantee the Company's access to any or all financing from EXIM.
  • All final commitments must be in compliance with EXIM policies as well as program, legal and eligibility requirements.

This Week in Transportation News: 12 Stories You Need to See

Retrieved on: 
Friday, July 21, 2023
The Henry Ford, Electricity, IC, Sale, EVS, Le Mans, Henry Ford, NASCAR, CTEP, Cummins, NTEP, Rail transport

NEW YORK, July 21, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the auto and transportation industries stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • The IC Bus® CE Series school bus elevates the brands' reputation for reliability, durability and serviceability, while delivering product and service design innovations.
  • The increased 83-passenger capacity school bus is available in both diesel (Cummins B6.7) and zero-emissions electric powertrain options.
  • A new world record has been set for the fastest-charging battery pack of 3 minutes and 56 seconds.
  • This technology will be housed in an InMotion Revolution LMP3 race car as part of the 24 Hours of Le Mans race and will be competing against gas-powered vehicles.

ABB E-mobility first to earn CTEP and NTEP certifications for DC fast chargers

Retrieved on: 
Thursday, July 20, 2023
NIST, EV, Electricity, DC, Measurement, ABB, AC, Sale, HB, Certification, EVS, National Institute of Standards and Technology, Vehicle registration plates of Nepal, Terra, Foreign policy, United, CTEP, NTEP, Medical device

Additionally, the California Division of Measurement Standards oversees the CTEP certification program for chargers operating within the state with similar compliance requirements.

Key Points: 
  • Additionally, the California Division of Measurement Standards oversees the CTEP certification program for chargers operating within the state with similar compliance requirements.
  • ABB E-Mobility's DC fast chargers, including its Build America, Buy America compliant chargers made in its Columbia, South Carolina facility can meet the metering requirements defined by these programs.
  • Production began early this year and Terra 184 DC fast chargers produced in South Carolina have already been installed along American highways.
  • ABB E-mobility collaborated with software partner Chargelab to meet the software compliance requirements for this CTEP certified AC charging solution.

ABB E-mobility expands solutions for public and fleet EV charging in North America

Retrieved on: 
Monday, June 12, 2023
Maintenance, Federal Highway Administration, EV, Senior, Internet, Original equipment manufacturer, Kw, DC, OCPP, ABB, AC, UL, Certification, EVS, Parity, CCS1, Buy America Act, CCS, TCO, CTEP, Safety, Electric motor, Video game, Hydraulic machinery, Electric battery

For scaling charging infrastructure, space constrained EV fleet charging depots require high power charging with flexible and footprint-efficient designs.

Key Points: 
  • For scaling charging infrastructure, space constrained EV fleet charging depots require high power charging with flexible and footprint-efficient designs.
  • Combined, these new offerings for North America build upon ABB E-mobility's EV charging technologies which thousands of facilities, public charging sites, fleet operations and transit depots have integrated into their e-mobility operations for over a decade.
  • "ABB E-mobility is committed to developing and deploying advanced charging technologies that are ready for the current and future requirements of public charging sites as well as the unique needs of every sized EV fleet," said Bob Stojanovic, Senior Vice President for ABB E-mobility in North America.
  • ABB E-mobility is enabling zero-emission mobility as a global leader in electric vehicle (EV) charging solutions for a more sustainable and resource-efficient future.

Zenith Epigenetics Reports Advancement of ZEN-3694 in NUT Carcinoma

Retrieved on: 
Thursday, June 1, 2023
CRPC, Neoplasm, Survival, NUT, CRADA, Quality of life, Lung cancer, Head, Prognosis, Carcinoma, NUT carcinoma, Neck, Bangladesh Technical Education Board, BET, Development, National Cancer Institute, Cancer, Cooperative research and development agreement, Patient, Colorectal cancer, Drug combination, Zenith, Diagnosis, CTEP, Ovarian cancer, Breast cancer, NCI, NIH, Disease, Pharmaceutical industry

Zenith's BET inhibitor ZEN-3694 providing significant clinical benefit in patients with aggressive cancer type

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - June 1, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") reports clinical activity and the advancement in development of its BET inhibitor (BETi) ZEN-3694 in patients with NUT carcinoma (NC).
  • Zenith Epigenetics has provided ZEN-3694 to two NC patients for compassionate use and both experienced significant clinical benefit and durable reduction of their tumors.
  • "We are very pleased that NUT carcinoma patients receiving ZEN-3694 for compassionate use have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.
  • We continue to advance these programs with our partners and are committed to bring this important therapy to these patients."

Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute

Retrieved on: 
Wednesday, March 8, 2023
Society, Infrastructure as code, GVHD, Development, Bangladesh Technical Education Board, ASH, Epstein–Barr virus, Bone marrow, Graft-versus-host disease, Collaboration, Cell, Therapy, Safety, Gene editing, Research, Immune system, Cooperative research and development agreement, Baylor College of Medicine, Non-Hodgkin lymphoma, Patient, NCI, CTEP, Baylor University, CRADA, Risk, NIH, Pharmaceutical industry, Diagnosis

Tessa is currently advancing a Phase 1 clinical trial in the United States investigating TT11X in CD30-positive lymphomas.

Key Points: 
  • Tessa is currently advancing a Phase 1 clinical trial in the United States investigating TT11X in CD30-positive lymphomas.
  • “We are pleased to enter into a CRADA with NCI,” said Tessa President and CEO Thomas Willemsen.
  • Tessa plans to extend its allogeneic EBVST platform to other cancer indications, including solid tumors.
  • CD30.CAR-modified allogeneic EBVSTs without gene editing have demonstrated a strong safety profile and efficacy in early trials with minimal risk of graft-versus-host disease (GVHD).

Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies

Retrieved on: 
Monday, February 6, 2023
Actinium, Bone marrow, AML, NCI, TP53, CRADA, Collaboration, Immunotherapy, Experiment, National Cancer Institute, Development, Bangladesh Technical Education Board, NIH, CTEP, NYSE, Radiation, Patient, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, Clinical trial, Lois, SWOG, Survival, Letter, American College, Acute myeloid leukemia, Cooperative research and development agreement, National Institutes of Health Clinical Center, Pharmaceutical industry

NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. Under the terms of the CRADA, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A while Actinium will be responsible for supplying and distributing Actimab-A to participating clinical sites and providing additional support as needed. The CRADA will provide broad support for the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel combinations, in line with Actinium's strategy of leveraging Actimab-A's targeted radiotherapy mechanism to elicit synergistic effects.

Key Points: 
  • The CRADA studies will be overseen by NCI in collaboration with Actinium's clinical development team.
  • Actimab-A studies may also be conducted through NCI's MyeloMATCH program.
  • Dr. Avinash Desai, Chief Medical Officer of Actinium Pharmaceuticals, commented, "NCI's broad support under the CRADA is a strong encouragement for us to together explore Actimab-A's potential for the treatment of AML and other hematologic malignancies.
  • We look forward to working collaboratively with the NCI and all investigators through this CRADA to complete multiple clinical trials to further realize Actimab-A's therapeutic potential."

Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)

Retrieved on: 
Monday, October 17, 2022
SAN, Physician, LinkedIn, U.S. Securities and Exchange Commission, Development, Royal commission, CTEP, Glioma, Breakthrough therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Hematological Cancer Research Investment and Education Act, Drug development, Cooperative research and development agreement, Twitter, CRADA, Security (finance), RAF, Investment, Orphan drug, Private Securities Litigation Reform Act, Food, Diagnosis, Adolescence, National Cancer Institute, Adult, Safety, GLOBE, EC, Forward-looking statement, MAPK, FDA, COVID-19, Cancer, European Commission, NCI, Pharmaceutical industry

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better.

Key Points: 
  • Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company that believes when it comes to pediatric cancer, we can do better.
  • Day One was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer.
  • Day One aims to re-envision cancer drug development and redefine whats possible for all people living with cancerregardless of agestarting from Day One.
  • Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments.